Dopamine D3 receptor variant and tardive dyskinesia

European Archives of Psychiatry and Clinical Neuroscience

Volumn 250, Issue 1, 2000, Pages 31-35

  Rietschel, Marcella ^a   Krauss, Harald ^a   Müller, Daniel J ^a   Schulze, Thomas G ^a   Knapp, Michael ^a   Marwinski, Karen ^a   Maroldt, Ansgar Otto ^a   Paus, Sebastian ^a   Grünhage, Frank ^a   Propping, Peter ^c   Maier, Wolfgang ^a   Held, Tilo ^b   Nöthen, Markus M ^a  

^a UNIVERSITY OF BONN   (Germany)

^b Mental State Hospital   (Germany)

^c NONE

Author keywords

Choreoathetotic movements; Genetics; Pharmacogenetics; Risk factor

Indexed keywords

DOPAMINE 3 RECEPTOR; NEUROLEPTIC AGENT; DOPAMINE 2 RECEPTOR; DRD3 PROTEIN, HUMAN; DRD3 PROTEIN, MOUSE;

ADULT; AGE; ARTICLE; CONTROLLED STUDY; FEMALE; GENE FREQUENCY; GENETIC SUSCEPTIBILITY; GENOTYPE; HEREDITY; HUMAN; HUMAN CELL; HYPERACTIVITY; LOCOMOTION; MAJOR CLINICAL STUDY; MALE; PHARMACOGENETICS; PRIORITY JOURNAL; RECEPTOR GENE; RISK FACTOR; SCHIZOPHRENIA; TARDIVE DYSKINESIA; ANIMAL; CHROMOSOME 3; DRUG EFFECT; DYSKINESIA; GENETIC PREDISPOSITION; GENETIC VARIABILITY; GENETICS; GERMANY; MOUSE; MOUSE MUTANT; PATHOPHYSIOLOGY; PHYSIOLOGY; PSYCHOSIS;

ADULT; AGE FACTORS; ANIMALS; ANTIPSYCHOTIC AGENTS; CHROMOSOMES, HUMAN, PAIR 3; DYSKINESIA, DRUG-INDUCED; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GERMANY; HUMANS; LOCOMOTION; MALE; MICE; MICE, KNOCKOUT; PHARMACOGENETICS; PSYCHOTIC DISORDERS; RECEPTORS, DOPAMINE D2; RECEPTORS, DOPAMINE D3; RISK FACTORS; SCHIZOPHRENIA; VARIATION (GENETICS);

EID: 0033621784     PISSN: 09401334     EISSN: None     Source Type: Journal    
DOI: 10.1007/PL00007536     Document Type: Article

References (38)

1. Accili D, Fishburn CS, Drago J, Steiner H, Lachowicz JE, Park BH, Gauda EB, Lee EJ, Cool MH, Sibley DR, Gerfen CR, Wetphal H, Fuchs S (1996) A targeted mutation of the D3 dopamine receptor gene is associated with hyperactivity in mice. Proc Natl Acad Sci USA 93:1945-1949
2. American Psychiatric Association (1994) Diagnostic and Statistical Manual of Mental Disorders. 4th edition. American Psychiatric Association Washington, DC
3. Asherson P, Mant R, Holmans P, Williams J, Cardno A, Murphy K, Jones L, Collier D, McGuffin P, Owen M (1996) Linkage, association and mutational analysis of the dopamine D3 receptor gene in schizophrenia. Mol Psychiatry 1:125-132
4. Barnes TRE, Braude WM (1985) Akathisia variants and tardive dyskinesia. Arch Gen Psychiatry 42:874-878
5. Belmaker RH, Bannet J, Brecher-Fride E, Yanai J, Ebstein RP (1981) The effect of haloperidol feeding on dopamine receptor number in ten mouse strains. Clin Genet 19:353-356
6. Casey DE (1995) Tardive Dyskinesia: Pathophysiology. In: Bloom FE, Kupfer DJ (eds) Psychopharmacology: The Fourth Generation of Progress. Raven Press, New York, pp 1497-1511
7. Clow JM (1980) Changes in cerebral dopamine treatment, long-term effects of neuroleptics. Adv Biochem Psychopharmacol 24:335-340
8. Endicott J, Spitzer RL (1978) A diagnostic interview: the schedule for affective disorders and schizophrenia. Arch Gen Psychiatry 35:837-844
9. 3 receptor gene: organization, transcript variants, and polymorphism associated with schizophrenia. Am J Med Genet 67:63-70
10. Gunne LM, Growdon J, Glaeser B (1982) Oral dyskinesia in rats following brain lesions and neuroleptic drug administration. Psychopharmacology 77:134-139
11. 3 receptors and use of antipsychotics in patients with schizophrenia. Arch Gen Psychiatry 54:225-232
12. Iversen SD, Howells RB, Hughes RF (1980) Behavioral consequences of long-term treatment with neuroleptic drugs. Adv Biochem Psychopharmacol 24:305-313
13. Jeste DV, Wyatt RJ (1982) Understanding and treating tardive dyskinesia. Guilford Press, New York
14. Jeste DV, Caligiuri MP (1993) Tardive dyskinesia. Schizophr Bull 19:303-315
15. Kane JM, Jeste DV, Barnes TRE, Casey DE, Cole JO, Davis JM, Gualtieri CT, Schooler NR, Sprague RL, Wetterstein RM (1992) Tardive dyskinesia: a task force report of the American Psychiatric Association. American Psychiatric Association, Washington DC
16. 3 receptor as a useful polymorphism for investigating psychiatric disorders. Psychiatr Genet 2:249-256
17. 3 receptor gene. Hum Genet 87:618-620
18. 3 receptor with the Semliki Forest virus system. Biochem Biophys Res Commun 225:1068-1072
19. Mithani S, Atmadja S, Baimbridge KG, Fibinger HC (1987) Neuroleptic-induced oral dyskinesias: effects of progabide and lack of correlation with regional changes in glutamic acid decarbosylase and choline acetyltransferase activities. Psychopharmocology 93:94-100
20. Nöthen MM, Propping P, Fimmers R (1993) Association versus linkage studies in psychosis genetics. J Med Genet 30:634-637
21. Risch N, Merikangas K (1996) The future of genetic studies of complex human diseases. Science 273:1516-1517
22. 3 receptor protein - No role in the genetic predisposition to bipolar affective disorder. Psychiat Res 46:253-259
23. Rosengarten H, Schweitzer JW, Friedhoff AJ (1994) Possible genetic factors underlying the pathophysiology of tardive dyskinesia. Pharmacol Biochem Behav 49:663-667
24. Schönecker M (1957) Ein eigentümliches Syndrom im oralen Bereich bei Megaphenapplikation. Nervenarzt 28:35
25. Schooler NR, Kane JM (1982) Research diagnosis for tardive dyskinesia. Arch Gen Psychiatry 39:486-487
26. Simpson GM, Angus JWS (1970) A rating scale for extrapyramidal side effects. Acta Psychiatr Scand (suppl) 212
27. Simpson GM, Lee JH, Zoubok B, Gardos G (1979) A rating scale for tardive dyskinesia. Psychopharmacology 64:171-179
28. Smith JM, Baldessarini RJ (1980) Changes in prevalence, severity, and recovery in tardive dyskinesia with age. Arch Gen Psychiatry 37:1368-1373
29. 3) as a target for neuroleptics. Nature 347: 146-151
30. Steen VM, Lovlie R, MacEwan T, McCreadie RG (1997) Dopamine D3 receptor gene variant and susceptibility to tardive dysinesia in schizophrenic patients. Mol Psychiatry 2:139-145
31. Tamminga CA, Dale JM, Goodman L, Kaneda H, Kaneda N (1990) Neuroleplic-induced vacuous chewing movements as an animal model of tardive dyskinesia: a study in three rat strains. Psychopharmacology 102: 474-478
32. Waddington JL, Cross AJ, Gamble SJ, Bourne RC (1982) Spontaneous orofacial dyskinesia and dopaminergic function in rats after 6 months of neuroleptic treatment. Science 220:530-532
33. Waddington JL, Youssef HA (1988) The expression of schizophrenia, affective disorder and vulnerability to tardive dyskinesia in an extensive pedigree. Br J Psychiatry 153:376-381
34. Weinhold P, Wegner J, Kane J. Familial occurence of tardive dyskinesia (1981) J Clin Psychiatry 42:165-166
35. Woerner MG, Alvir JMJ, Saltz BL, Lieberman JA, Kane JM (1998) Prospective study of tardive dyskinesia in the elderly: rates and risk factors. Am J Psychiatry 155:1521-1528
36. Yassa R, Ananth J (1981) Familial tardive dyskinesia. Am J Psychiatry 138:1618-1619
37. Yassa R, Jeste DV (1992) Gender differences in tardive dyskinesia: a critical review of the literature. Schizophrenia Bull 18: 701-715
38. Youssef H, Lyster G, Youssef F (1989) Familial psychosis and vulnerability to tardive dyskinesia. Int Clin Psychopharmacol 4: 323-328